BofA lowered the firm’s price target on Moderna (MRNA) to $25 from $26 and keeps an Underperform rating on the shares. For Q1, the firm made no material changes to its model ahead of earnings, but for 2025 its revenue forecast has decreased by 10%, primarily due to lower U.S. COVID sales as a result of updated recommendations, the analyst tells investors in a preview.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA: